Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular carcinoma, Transarterial chemoembolization, Immunotherapy
Brief summary
This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization with drug-eluting beads(TACE-DEB) in patients with BCLC Stage A/B Hepatocellular Carcinoma Beyond the Milan Criteria.
Detailed description
Patients with hepatocellular carcinoma (HCC) of BCLC stage A/B exceeding the Milan criteria have a low resection rate and high postoperative recurrence rate, therefore, optimizing therapy for these patients is an important unmet need. This study aimed to investigate the efficacy and safety of preoperative DEB-TACE plus sintilimab for the treatment of patients with BCLC stage A/B HCC exceeding the Milan criteria.
Interventions
DRUGSintilimab
Sintilimab: 200mg iv Q3W D1
DRUGDEB-TACE
DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
Sponsors
Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A Phase II Single-arm, Open-label Study
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 18 years and 75 years; 2. ECOG PS 0/1; 3. Patients with histologically- or clinically-confirmed HCC (based on the American Association for the Study of Liver Diseases criteria) that was either BCLC stage A and exceeded the Milan criteria, or BCLC stage B 4. Have not received any anti-tumor systemic treatment in the past 5. No contraindications for the treatment of DEB-TACE and PD-1 inhibitors; 6. Liver function: Child-Pugh score Class A 7. The expected survival of the patient is more than 3 months 8. The following conditions must be met: Platelets ≥ 75 × 10\^9/L White blood cell count (WBC) ≥ 3.0 × 10\^9/L Hemoglobin ≥ 90 g/L Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin (TBIL) ≤ 1.5 × ULN Blood creatinine ≤ 1.5 × ULN PT prolonged ≤ 3 s 9. Adequate bone marrow, cardiac, and renal function 10. Patients must agree to accept postoperative follow-up required by the design of this study; 11. Patients must have the ability to understand and voluntarily sign the informed consent, and must sign an informed consent before starting any specific procedure for the study.
Exclusion criteria
1. History of other malignancies； 2. In combined with severe heart, lung, kidney or other important organ dysfunction, or combined with serious infection or other serious associated diseases, that cannot tolerate treatment (\> CTCAE Version 5.0 adverse events of grade 2)； 3. With uncontrolled hepatitis B (HBV-DNA\>2000 IU/ml and elevated ALT). 4. Spontaneous rupture and bleeding of HCC 5. Hepatic tumor burden \>50% total liver volume 6. Complete occlusion of the portal vein 7. Evidence of a bleeding diathesis or coagulopathy, active infections, and autoimmune disease 8. Recurrent disease after surgery within the last 5 years 9. History of organ transplantation or plan to have liver transplantation; 10. Pregnant women, nursing mothers. 11. Patients have other factors that may interfere with patient enrollment and assessment results. 12. Refuse follow-up as required by this study protocol and refuse to sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) per mRECIST | 36 months | The duration from treatment initiation to PD in patients who cannot undergo surgery, or to the date of postoperative relapse in patients who receive surgery, or death for any reason, whichever occurs first (according to mRECIST). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 36 months | The duration from treatment initiation to death from any cause. |
| Pathological Response | 6 months | Including Major Pathological response rate（MPR）and pathological complete response (pCR). MPR is defined as the presence of 10% or fewer viable tumour cells in the primary tumours. pCR is defined as no viable tumour cells in the specimen. |
| 12 mo PFS rate | 36 months | The percentage of patients who have not progressed or relapsed or death at the 12 mo time point since the first time of treatment. |
| Disease Control Rate (DCR) per mRECIST | 36 months | The proportion of complete response, partial response or stable disease as optimal response among all treated patients according to mRECIST. |
| Adverse events (AEs) | 36 months | The incidence, relationship with study drugs, and severity level of all adverse events (AEs) according to CTCAE 5.0, treatment-emergent adverse events (TEAEs), treatment related adverse events (TRAEs), and serious adverse events (SAEs) and the changes in vital signs, physical examination results, and laboratory test results before, during, and after the treatment. |
| Objective Response Rate (ORR) per mRECIST | 36 months | The proportion of complete response or partial response as optimal response among all treated patients according to mRECIST. |
Countries
China
Outcome results
None listed